Article

A Prescription for Active Surveillance of Prostate Cancer

Leonard Gomella, chair of the urology department and director of the Kimmel Cancer Center Network, explains active surveillance when it comes to a prostate cancer diagnosis.

Leonard Gomella, chair of the urology department and director of the Kimmel Cancer Center Network at Jefferson University Hospitals, explains active surveillance when it comes to a prostate cancer diagnosis.

"Not all patients with prostate cancer require aggressive treatment," he says. "If, in meeting with your doctor, they discuss with you active surveillance versus actively treating the tumor, they need to really explain to you what active surveillance is. It's not that they're ignoring you, but it's keeping an eye on the cancer."

Active surveillance may be different for each practice, but "in general, it's a PSA (prostate-specific antigen test) and a rectal exam about every six month, and every year or two a biopsy of the prostate," he says.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content